Epithelioid glioblastomas (E-GBMs) manifest BRAF V600E mutation in up to 50% of cases, compared with a small percentage of ordinary GBMs, suggesting that they are best considered variants rather than a different pattern of GBM. Availability of a targeted therapy, vemurafenib, may make testing BRAF status important for treatment. It is unclear whether BRAF VE1 immunohistochemistry (IHC) can substitute for Sanger sequencing in these tumors. BRAF VE1 IHC was correlated with Sanger sequencing results on our original cohort of E-GBMs, and then new E-GBM cases were tested with both techniques (n = 20). Results were compared with those in similarly assessed giant cell GBMs, anaplastic pleomorphic xanthoastrocytomas. All tumors tested showed 1:1 correlation between BRAF V600E mutational results and IHC. However, heavy background immunostaining in some negatively mutated cases resulted in equivocal results that required repeat IHC testing and additional mutation testing using a different methodology to confirm lack of detectable BRAF mutation. Mutated/BRAF VE1 IHC + E-GBMs and anaplastic pleomorphic xanthoastrocytomas tended to manifest strong, diffuse cytoplasmic immunoreactivity, compared with previously studied gangliogliomas, which demonstrate more intense immunoreactivity in the ganglion than in the glial tumor component. One of our E-GBM patients with initial gross total resection quickly recurred within 4 months, required a second resection, and then was placed on vemurafenib; she remains tumor free 21 months after second resection without neuroimaging evidence of residual disease, adding to the growing number of reports of successful treatment of BRAF-mutated glial tumors with drug. E-GBMs show good correlation between mutational status and IHC, albeit with limitations to IHC. E-GBMs can respond to targeted therapy.
Tucson, AZ; bought out from Spring Biosciences Inc., Pleasanton, CA). After first demonstrating the principle that BRAF VE1 IHC might correlate with positive or negative Sanger sequencing in our original cohort, 11 we extended our study to new cases of E-GBMs accrued since that publication as well as a subset of our original A-PXAs, which we had also previously assessed by Sanger sequencing but not IHC. 8 We then compared the pattern of immunostaining we saw in these tumor types with our recently published experience with gangliogliomas immunostained with the same antibody. 15, 16 MATERIALS AND METHODS
Case Accrual
All available immunoblank slides were retrieved from our files from our original E-GBMs and giant cell GBMs assessed by Sanger sequencing for BRAF V600E mutation, 11 as were those from A-PXAs we had similarly studied. 8 Many of the original cases 8, 11 had been outside consultation cases, and thus not all examples tested by Sanger sequencing for those studies still had immunoblank slides or paraffin blocks remaining in our archives and available for the current study.
After testing our previously published materials, we went forward with IHC and Sanger sequence testing on newly accrued cases, focusing on new cases of E-GBMs seen since our original publications. 9, 11 All diagnoses had been made by the author (B.K.K.-D.).
Routine Histology and IHC
Tissues were fixed in 10% buffered formalin and cut into 5-mm-thick sections; all staining/immunostaining analyses were performed on formalin-fixed, paraffin-embedded (FFPE) sections and not frozen material. Immunostains utilized for diagnostic purposes at the time of original assessment included GFAP (Dako Corporation, Carpinteria, CA; polyclonal, 1:2500, no antigen retrieval), MIB-1 (Dako; monoclonal, 1:400 dilution, antigen retrieval), IDH1 (Histobiotec, Miami Beach, FL; monoclonal, antigen retrieval), p53 (Dako; monoclonal, 1:200, antigen retrieval), and, in many instances, S100 (Ventana; monoclonal, predilute, antigen retrieval) and synaptophysin (Ventana; polyclonal, predilute, antigen retrieval).
The available original E-GBMs and giant cell GBMs from our previous paper 11 were retrospectively immunostained for BRAF VE1 (Ventana; monoclonal, antigen retrieval); these represented cases both with and without the BRAF V600E mutation as originally assessed by Sanger sequencing for BRAF V600E mutation (see below). BRAF VE1 immunostaining was automated and conducted on a Benchmark Ultra stainer from Ventana/ Roche, utilizing the proprietary antigen retrieval solution necessary for this equipment as provided by the company, which is of high pH (8.5) . All immunostained sections were counterstained with hematoxylin. All newly accrued cases of E-GBMs were also both immunostained for BRAF VE1 and assessed for BRAF V600E mutation by Sanger sequencing (see below). Equivocal results for IHC were repeated, and, whenever possible, fresh-cut slides from the paraffin block were utilized in retesting equivocal results.
Repeated attempts were also made to optimize our IHC methodology in an attempt to reduce equivocal findings, with another immunostaining methodology, the Optivision system; despite using several different concentrations and retrieval methods, this system proved unsatisfactory in our laboratory and was not further pursued.
Methods for Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) had been conducted as part of the routine workup at the time of diagnosis in most E-GBM cases. Briefly, dual-color FISH probe sets, manufactured by Vysis (Abbott Laboratories Inc., Des Plaines, IL), were used for amplification status of EGFR. To test for monosomy 22, DNA probes directed to 22q11.2 and 22q13 were used; this method detects most deletions but does not detect point mutations in chromosome 22. For analysis of PTEN, a PTEN (10q23)-specific DNA probe and a probe directed to the chromosome 10 centromere were used.
DNA Sequencing for BRAF Exon 15 Mutation
In all cases, optimal areas of tumor were identified by the author (B.K.K.-D.), microdissected using microscope-assisted manual microdissection as needed, and utilized for mutational testing, with microdissection of these areas to ensure that the testing was performed on areas enriched for at least 50% tumor cells.
DNA was extracted from FFPE material using the DNeasy FFPE extraction kit (Qiagen Inc., Valencia, CA) according to manufacturer's instructions. DNA yields were then quantified using a Nanodrop spectrophotometer ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA).
For direct sequencing, approximately 10 ng of template DNA was polymerase chain reaction (PCR) amplified using 5 pmol each of forward (5 0 TGCTTGCTCTGATAG GAAAAT3 0 ) and reverse (5 0 TCAGGGCCAAAAATTTA ATCA3 0 ) BRAF exon 15 primers KAPA2G Robust Hot-Start Enzyme and PCR master mix with KAPA dNTP mix (KAPA Biosystems cat# KK5525 and KK1017) in a 25 mL reaction. PCR was performed on an ABI 9700 thermocycler with an initial denaturing step at 951C, followed by 20 cycles of touchdown PCR (starting annealing temperature of 651C, decremented 0.51C per cycle) and 25 cycles at 941C denaturation, 551C annealing, and 721C extension finished by a 10-minute 721C final extension. The resultant PCR products were purified with the QIAquick 96-well PCR cleanup kit (Qiagen cat# 28106). The purified PCR products were sequenced in forward and reverse directions using an ABI 3730 automated sequencer using BigDye Terminator Version 1.1 (Applied Biosystems). Each chromatogram was visually inspected for any abnormalities, using NM_004333.4 as a reference sequence, with particular attention directed to codon 600. Sequences were also evaluated using Mutation Surveyor software (Soft Genetics, State College, PA). Mutations were determined to be present when peaks reached a threshold value above baseline calculated from the background level, combined with visual inspection of the chromatogram.
SNaPshot Mutational Assessment
Single nucleotide base extension (SNaPshot, Life Technologies Inc, Carlsbad, CA) assessment for BRAF c.1799T mutation, an assay with higher analytic (technical) sensitivity compared with Sanger sequencing, was performed on the subset of cases with equivocal IHC but negative Sanger results, with methods identical to those utilized in our previous study. 16 
RESULTS

Patient Cohort
Of the original published cohort, 11 9 of 15 E-GBMs (2 negative for mutation, 7 positive for mutation) and 8 of 9 giant cell GBMs (all negative for mutation) had sufficient material remaining in our files for BRAF VE1 IHC testing. Of the original published A-PXA cohort, 8 6 of 10 cases assessed by Sanger sequencing were available for BRAF VE1 IHC (4 positive, 2 negative for mutation).
Eleven new cases of E-GBMs were identified, making a total of 20 total E-GBMs tested by both techniques. Clinical and demographic features are provided in Table 1 . The overall age range for the E-GBM cohort in which both BRAF VE1 IHC and Sanger sequencing results were available was 10 to 82 years, with 6 patients aged below 30 years, younger than most GBMs 10 ( Table 1) .
Of the newly accrued cases, 7 of the 11 new E-GBMs represented consultation cases from outside hospitals (Table 1) , with 1 seen as a consultation biopsy case from an outside hospital with subsequent resection at our facility (case 19). Although the majority of E-GBM cases were consultation cases, it is important to note that these cases had not been specifically submitted to rule out E-GBM, that is, they came from regional hospitals that often submit brain biopsy specimens to us for diagnosis. Thus, these cases of E-GBMs were not exceptional and had come up in routine community hospitals in daily practice, underscoring that the E-GBM subtype is not exceedingly rare. All but 1 of these had been referred with the suspicion of high-grade glioma. The exception was a case that had originally been diagnosed at the outside hospital as a metastatic melanoma to the brain until her case had been presented at the local Tumor Board at the referring hospital and it became evident that she did not have an antecedent history of melanoma (case 17). The brain biopsy was then submitted to our institution for a second opinion. Unlike our original series in which we focused primarily on relatively "pure" E-GBMs, in this study we expanded our cohort to include those with more focal epithelioid features (n = 5, cases 12, 13, 18, 19, 20) .
One of our original E-GBM patients with tumor showing BRAF mutation has, since publication, been treated with the targeted drug vemurafenib (case 5). Her original tumor showed the characteristic relatively demarcated, mixed cystic and solid features typical of many E-GBMs, 11 with the cyst highlighted on the T2-weighted magnetic resonance imaging (MRI) scans ( Fig. 1A ) and the enhancement on T1-weighted MRI with gadolinium ( Fig. 1B ). She underwent a gross total surgical resection of tumor, followed by postoperative radiation therapy. She suffered a rapid recurrence despite these treatments, 5 months after initial surgery and <3 months after completion of radiation. MRIs after this recurrence showed new signal in the tumor bed (Figs. 1C, D). She underwent a second gross total resection. Tumor recurrence rather than therapyinduced necrosis was confirmed by pathology. No further radiation therapy could be given, and no conventional chemotherapy was administered; she instead received treatment with vemurafenib, to a dose of 960 mg twice daily as her only therapy. She is still receiving this medication 23 months after recurrence, with an excellent quality of life. MRI scans show no recurrence after receipt of drug (Figs. 1E, F, at 19 mo after second surgery); her most recent scan at 23 months was also negative for recurrent/progressive tumor.
Histology Results
Histologic features detailed in our original E-GBM and giant cell GBM paper 11 and in our A-PXA paper 8 on those cohorts are not repeated here. Six of the 11 new E-GBMs were almost identical histologically to cases in our original series, 11 and these tumors contained a majority of epithelioid tumor cells and had been "pure" E-GBMs. The 6 new "pure" E-GBM cases demonstrated the pathognomonic cohesive sheets of patternless, closely packed ( Fig. 2A) , variably lipidized, small to medium-sized cells with rounded cytoplasmic profiles, eosinophilic cytoplasm, lack of cytoplasmic stellate processes, and absence of interspersed neuropil ( Fig. 2B ). As previously described, 11 GFAP could be quite variable from one area to another in the tumor or between cells ( Fig. 2C ). Necrosis was often not associated with pseudopalisading of tumor cells or with prominent microvascular proliferation ( Fig. 2D ). Both limited individual cell infiltration into the surrounding parenchyma and occasional perivascular tumor spread ( Fig. 2E ) could be found. Nineteen of 20 cases were negative for IDH1 by IHC; the sole positive case was a secondary GBM as previously reported from our original paper. 11 Five of 11 of our new cases manifested a less-pure, more focal epithelioid phenotype. Case 12 had relatively discrete areas with small epithelioid cells ( Fig. 2F ) and others with giant cell features, with the latter showing non-neoplastic lymphocytes (Fig. 2F ). Case 13 manifested a rich admixture of epithelioid and spindled, pleomorphic cells in a few regions ( Fig. 2G ), but in most of the tumor the predominant population was that of elongate, pleomorphic cells (Fig. 2I ). Cases 18, 19 , and 20 all had focal epithelioid features with either admixtures of fibrillary (cases 18, 19) or large pleomorphic tumor cells (case 20). Case 20 was notable as it was a radiation-induced GBM of the cerebellum in a patient with a remote history of ependymoma in childhood for which he had received radiation therapy. Although only 2 of these 5 mixed cases eventually proved to have the BRAF V600E mutation (see below), this suggests that even when the epithelioid 
FISH Results
FISH had been conducted in most of the E-GBM cases as part of the original diagnostic assessment (17/ 20; Table 1 ) and, as available, we provide those results ( Table 1) . FISH results in our larger E-GBM cohort confirm our original impression 11 that no particular pat-tern is characteristic of E-GBMs, except possibly that EGFR amplification in more than a few rare cells was uncommon but PTEN abnormalities are present in most examples. Specifically, EGFR amplification was identified in only 2 cases (cases 1 and 18) showing amplification and 2 cases (cases 9 and 1) possessing rare cells with EGFR amplification; the remaining 11 cases tested for EGFR amplification by FISH were negative. Abnormalities in PTEN were more frequent, with 8 of 12 cases tested by FISH showing loss of PTEN, albeit with 2 cases (case 4 Immunostaining of the original cohort is illustrated in Figure 3 , and the bright red chromagen yielded intensely positive results in tumor but not in adjacent dura (Fig. 3A ), blood vessels ( Fig. 3B ), or necrotic foci (Fig. 3C) in the same section. Immunostaining was diffuse, crisp, usually of uniform intensity throughout the cytoplasm of tumor cells, and highlighted the epithelioid phenotype (Fig. 3D) . Two of the 7 immunopositive original cases showed variability in staining quality in the tissue, but we noted that these were the oldest cases in our series (cases 1, 2), and the immunoblank slides available in our archives for testing may have been of the oldest age. Tissue did not remain in the block for newer sections. Both, however, showed convincing positive immunostaining in some regions of the tissue. One of these E-GBMs additionally showed some variability in intensity of immunostaining from cell to cell (Fig. 3E , case 2 illustrated). Two of the assessable cases had been negative for BRAF mutation and were also negative by IHC ( Fig. 3F, case 9 illustrated) . New E-GBMs further highlighted the uniform immunostaining with BRAF VE1 IHC, with sparing only of nontumorous areas on the slide (Fig. 4A ). With use of immunoblank slides <2 years of age in our archives, all tumor areas were uniformly immunoreactive on the slide (Fig. 4B) . Two of the 5 cases with focal epithelioid features (case 12 with epithelioid [ Fig. 2E ] and giant cell features [ Fig. 2F ]; case 13 with an admixture of epithelioid and pleomorphic cells [ Fig. 2H ]) as well as nonepithelioid areas (Fig. 2I ) showed diffuse uniform immunostaining in both tumor components (Fig. 4C) . The other 3 were initially equivocal by IHC (Fig. 4D) , although subsequent repeat immunostaining on the same section suggested that these were likely negative. Nevertheless, we further tested these 3 equivocal E-GBMs by a technique with greater analytic (technical) sensitivity, SNaPshot, on the possibility that they represented cases with lower mutational burden than could be detected by Sanger sequencing. These 3 cases were also negative for mutation by this technique (cases 14, 18, 20) .
Reassessing clinical and demographic features with the IHC/mutational results above showed that of the 11 mutated/IHC + E-GBM cases, 6 were female, and 5 were male ( Table 1) . Most of the patients below 30 years of age in the study did show mutation/IHC + (5/6 examples), but the overall cohort numbers are clearly too small for firm conclusions.
All 8 assessable giant cell GBMs were negative, all of which were assessed on freshly cut immunoblank slides prepared from paraffin blocks still available in our archives.
We were able to immunostain 6 of our 10 original A-PXAs, 8 and there was 1:1 concordance in 6 of 6 cases, albeit with more variation in immunostaining intensity throughout the slide than for our E-GBMs. Once again, fresh-cut slides from the block were necessary in all cases to achieve concordant IHC results with the known mutational status (4 originally positive, 2 negative for mutation). Although the numbers of these cases were small (n = 6), it appeared that, although the immunostaining was also uniform throughout the tumor population, it appeared to be weaker in intensity than what we generally encountered for immunopositive E-GBMs.
Gangliogliomas (GGs) as previously reported by our group 15 showed that immunopositive cases manifest stronger immunoreactivity in the ganglion cell component (Fig. 4E ) than in the glial component, but never in the glial cell component alone. Indeed, the strong immunostaining in positive cases served to highlight the neoplastic ganglion cells, but in negatively mutated/negatively immunostained cases, both tumor components were equally negative (Fig. 4F) .
Thus, limitations in immunostaining exist with this commercial antibody, at least in our hands, even after multiple diligent attempts made to optimize parameters of the staining technique. First, very strong diffuse, crisp cellular immunostaining results with the red chromagen were indisputably positive and were able to be achieved in our study with all mutationally positive new E-GBMs as well as our original E-GBMs. Some loss of antigen fidelity with older-cut archival slides was noted. Second, negative IHC correlated with negative mutational status in almost all examples; however, experience is required to interpret the immunostain because of the background staining that sometimes occurs. Heavy background staining leads to equivocal results in some cases. We first tried repeating the IHC procedure but then further assessed equivocal cases by Sanger sequencing. In this study the "heavy background cases" ultimately proved negative by mutational testing even with SNaPshot. Thus, given the (H&E) . B, This same case at higher magnification shows the typical rounded cytoplasmic profiles, eosinophilic cytoplasm, lack of cytoplasmic stellate processes, and absence of interspersed neuropil. Case 10 illustrated (H&E). C, GFAP could be quite variable from one area to another in the tumor and from one cell to the next. Case 10 illustrated. Immunostaining for GFAP with light hematoxylin counterstain. D, Most of our E-GBM cases manifested near-pure populations of epithelioid cells, usually of small to medium size; necrosis (lower right) was usually not associated with pseudopalisading of tumor cells or microvascular proliferation. Case 11 illustrated (H&E). E, In a few cases in which adjacent brain tissue was included with the tumor resection material, perivascular tumor spread could be found. Case 11 illustrated (H&E). F, Two of our new cases manifested a less-pure epithelioid phenotype. Case 12 had relatively discrete areas with epithelioid cells of small to medium size (H&E). G, Other areas from the same case showed classic features of giant cell GBM, even with coassociated non-neoplastic lymphocytes. Case 12 illustrated (H&E). I, Case 13 manifested a rich admixture of epithelioid and pleomorphic cells in some areas (H&E). J, Other areas from the same case consisted solely of elongate, pleomorphic cells, and these areas were more prevalent (H&E). H&E indicates hematoxylin and eosin.
importance of accurate documentation of BRAF mutational status before potential use of targeted therapy, we continue to test cases with heavy background/"hue" by mutational analysis, accompanied by microdissection to ensure an appropriately high proportion of tumor in the tested sample.
DISCUSSION
Combining our newly assessed E-GBMs (11 cases) with our original cohort 11 (13 cases), we show that 7/13 original and 4/11 new E-GBMs (11/24, 46%) are mutated for BRAF V600E. There were no significant differences in histologic features between BRAF-mutated and nonmutated examples, and now with our larger numbers of cases, there are also no significant demographic differences. We further extended our genetic assessment of E-GBMs, finding loss of PTEN more frequent than EGFR amplification. In tested E-GBMs, there was concordance between strong, crisp BRAF VE1 IHC and positive Sanger sequencing results. We also show in this study that reasonable IHC results occur for A-PXAs, although the available cohort for testing (n = 6) was too small for strong conclusions.
It is not known what mutational event leads to epithelioid formation in high-grade gliomas, although a recent, in-depth study of a single case by array comparative genomic hybridization separately performed for epithelioid versus nonepithelioid areas of a GBM hinted at possibly causation. 17 Specifically, Nobusawa et al 17 demonstrated BRAF V600E mutation both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells in the same tumor. In contrast, 8 shared copy number alterations and 3 copy number alterations were observed only in epithelioid cells; 1 of the latter was a homozygous deletion of a tumor-suppressor gene, LSAMP, at 3q13.31. 17 Thus, the BRAF mutation was not confined to the epithelioid component, even when confined to focal areas within a tumor. This parallels our findings in this study in that the 2/5 cases with focal epithelioid features that were BRAF VE1 IHC positive showed strong uniform immunostaining in both tumor components.
BRAF VE1 antibody results were reported by Koelsche et al 18 in a 2013 study in which GGs were assessed. Protein expression was predominantly identified in the ganglion cell component of the tumor, but no case showed immunostaining in the glial component alone. 18 We found that a similar IHC pattern exists in pediatric brainstem gliomas 15 and conversely noted that widely metastatic GGs of the spinal cord in adults were both VE1 IHC and Sanger sequencing negative for BRAF, all using the same laboratory and techniques. 16 In contrast, in E-GBMs, as well as the few A-PXAs we had available for the current study, the distribution of immunostaining was usually more uniform and diffuse than what was seen in GGs. There was a good correlation in our E-GBMs (n = 17), giant cell GBMs (n = 8), and A-PXAs (n = 6) between the IHC and Sanger sequencing results but with significant limitations in the antibody.
Background immunostaining results in a subset of cases required repeat immunostaining despite every attempt at optimization of the protocol. Our experience of difficulty with the BRAF antibody parallels those reported by others. [19] [20] [21] [22] Specifically, in colorectal cancers the authors had to optimize conditions, but when this was done, similar to our study, there was excellent concordance between IHC and mutational results (using the antibody from Spring Biosciences). 22 Interestingly, 1 of 4 of their cases that had been scored as having weak immunostaining proved to have BRAF V600E mutation, 22 also underscoring the need to follow up the occasional weak/equivocal result to appropriately classify mutational status. They further studied the optimal antigen retrieval method and found it to be with EDTA buffer (pH 6.0). 22 This parallels our use of high pH buffer and the proprietary buffer from the same manufacturer.
Concordance between IHC and mutational analysis with pituitary tumors has not been good. [19] [20] [21] To our knowledge, there is no currently well-documented, alternate biological reason for immunopositive BRAF VE1 immunostaining in a tumor except for the presence of BRAF V600E mutation, and thus we feel the background immunostaining is likely technical and not due to an alternative pathway that upregulates BRAF protein expression. We also do not favor a low-level mutation in these equivocal cases, as SNaPshot testing was also negative. We specifically microdissected optimal tumor areas for mutational testing, and thus dilution by nontumoral elements is unlikely to account for negative results in the 3 cases with equivocal IHC. Although heterogeneity for BRAF mutation is a possible explanation for discordant IHC and mutational results, this study specifically shows that BRAF protein expression (using a mutation-specific antibody) appears to be quite homogenous throughout the tumor population in E-GBMs, even in nonpure cases, thus leading to the likely explanation that, when the positive results of immunostaining represent true positive findings for BRAF mutation, the cells are homogenously impacted.
As of 2014, we recommend using IDH1 antibody differently from the BRAF VE1 antibody. With IDH1 IHC, when the result is clearly immunopositive (and in our experience the immunostain has high fidelity and is usually easy to interpret, with either all tumor cells positive or negative), then no additional mutational confirmation is necessary. If IDH1 IHC is negative, then mutational testing for IDH1/IDH2 mutation should be done in select patient groups including younger patients to rule out the rare types of IDH1/IDH2 mutation not detected by the antibody; a predictive algorithm has been recently developed and is online for directing IDH1/2 testing. 23 For BRAF VE1 IHC, completely negative IHC appears to preclude the need for mutational testing for BRAF V600E, at least when fresh-cut blanks are utilized. Thus far, all very strongly IHC + E-GBM cases in our experience equate with the positive presence of BRAF V600E mutation. However, heavy background/"hue" IHC occurs more often than is desirable, even with antibody optimization. We first repeat IHC testing and then, if still equivocal, proceed to mutational assessment by molecular methods. This recommendation of proceeding to mutational assessment in cases with equivocal/weak IHC is concordant with the recommendation for colorectal tumors. 22 The possibility of development of more high-fidelity antibodies in the future may improve IHC results and reduce equivocal cases, but given the fact that a therapy (vemurafenib) is potentially going to be given to a patient on the basis of IHC, mutational confirmation may still be desirable or required in the future.
Finally, the need for a more cost-effective method for screening BRAF mutational status in a significant subset of different glial tumor types is obvious. Although anecdotal, BRAF IHC immunopositive/Sanger sequencing-positive glial tumors have shown clinical response with the targeted therapy, vemurafenib. Although this favorable response to therapy has been well established in BRAF-mutated patients with metastatic melanoma, 13, 14 it is unlikely that large cohorts of far less common E-GBMs, A-PXAs, or even GGs can be similarly accrued in a rapid manner without multi-institutional efforts.
Indeed, to date, although only individual reports of patients with these uncommon brain tumor types and BRAF mutation responsive to vemurafenib have appeared, [24] [25] [26] [27] [28] [29] the evidence is accumulating that the drug is effective in various types of BRAF-mutated glial tumors. These have included 2 pediatric anaplastic supratentorial GGs (both with illustrated BRAF IHC + ), 24 a pediatric brainstem GG, 25 a pediatric GBM, which interestingly also had focal epithelioid features (Fig. 2C ), 26 4 of 5 treated adult recurrent or progressive PXAs, 27,28 a pilomyxoid astrocytoma, 29 and now an adult E-GBM. We acknowledge in our treated patient, that E-GBMs are often well demarcated and relatively noninfiltrative, and therefore the relative roles of gross total surgical excision versus vemurafenib therapy in our patient are somewhat difficult to parcel out. But we do note that our patient had undergone gross total resection and postoperative radiation therapy the first time, with rapid recurrence within 3 months of therapy completion, whereas the second gross total resection was only followed by the targeted drug, which led to sustained response. Therefore, in this otherwise aggressive tumor we feel that vemurafenib may have had efficacy. Furthermore, we have seen a recurrent pediatric A-PXA with BRAF mutation (but not included in our study of adult A-PXAs 8 ) with stabilization on drug (unpublished observation, N.K.F., 2014). Collectively, this suggests the potential for targeted therapy, a particularly exciting prospect in WHO grade IV gliomas such as E-GBMs, even if a less-frequent GBM tumor type.
